期刊文献+

阿托西班防治早产的药品不良反应/事件文献分析 被引量:7

Literature Analysis of Adverse Drug Reaction/Event Induced by Atosiban in the Treatment of Preterm Labor
原文传递
导出
摘要 目的:探讨阿托西班应用于早产时其药品不良反应/事件(ADR/ADE)的表现及发生规律,为其临床合理用药提供参考。方法:全面检索该药用于防治早产的所有国内、外临床研究,并对其出现的母体与新生儿ADR/ADE分别进行系统整理与分析。结果:阿托西班涉及母体的ADR/ADE主要为用药部位损害(47.11%)、胃肠系统损害(22.99%)、心率及心律紊乱(7.93%)、代谢和营养障碍(6.68%)等,具体表现为注射部位局部反应、恶心、呕吐、高血糖、心动过速等;涉及新生儿的ADR/ADE主要为呼吸系统损害(44.80%)、心外血管系统损害(9.27%)、胎儿异常(8.99%)及代谢和营养障碍(8.85%),具体表现为新生儿呼吸窘迫综合征、窒息、脑出血、动脉导管开放、低血糖、脓毒病、贫血等。阿托西班在东亚人群中最常见的不良反应为高血糖(7.25%)、心动过速(3.62%)、恶心(2.17%)、头痛(2.17%)、胸痛(2.17%)、呼吸困难(1.45%)及心悸(1.45%)等。结论:阿托西班在防治早产时可发生多种ADR/ADE,临床应用时需重视其安全性。 OBJECTIVE: To analyze and investigate the manifestations and regularity of adverse drug reactions/effects (ADR/ ADE) of atosiban applied in preterm labor, and to provide reference for rational drug use in the clinic. METHODS: Clinical trails about atosiban in the treatment of preterm labor were collected at home and abroad, maternal and neonatal/infant ADR/ADE of ato- siban were summarized and analyzed. RESULTS: The maternal ADR/ADE primarily contained application site disorders (47.11%), gastro-intestinal system disorders (22.99%), heart rate disorder or arrhythmia (7.93%), metabolism disorder and al- ogotrophy (6.68%), etc., presenting as application site reactions, nausea, vomiting, hyperglycemia, tachycardia, etc. The infant ADR/ADE mainly contained respiratory system damage (44.80%), vascular damage (9.27%), fetal abnormality (8.99%) and me- tabolism disorder and alogotrophy (8.85%), presenting as respiratory distress syackome, ap^ea, eerebra~ hemorrhage, patent due- ms arteriosus, hypoglycemia, sepsis, anaemia, etc. The most frequently occurred ADR/ADEs of atosiban in East Asian population were hyperglycemia (7.25%) , tachycardia (3.62%), nausea (2.17%), headache (2.17%), chest pain (2.17%), dyspnoea ( 1.45% ) and palpitation ( 1.45% ), etc. CONCLUSIONS: Atosiban can cause a variety of ADR/ADE in the treatment of preterm la- bor, so we should pay attention to its clinical safety.
出处 《中国药房》 CAS CSCD 2014年第14期1304-1307,共4页 China Pharmacy
关键词 阿托西班 药品不良反应 药品不良事件 早产 安全性 Atosiban Adverse drag reaction Adverse drug events Preterm labor Safety
  • 相关文献

参考文献32

  • 1王晓茵,刘雅婧.11769例住院新生儿疾病构成及死亡原因分析[J].中华儿科杂志,2003,41(7):551-552. 被引量:55
  • 2庄武.环状肽催产素竞争性拮抗剂 保胎药 阿托西班(atosiban)[J].国外医药(合成药.生化药.制剂分册),2001,22(4):251-252. 被引量:1
  • 3国家药品不良反应中心,国家食品药品监督管理局药品评价中心.WHO药品不良反应术语集[M].北京:中国医药科技出版社,2002:1-172.
  • 4Shim N, Park YW, Yoon BH, et al. Multicenter, parallel group, randomized, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women[J]. Britishl J of Obstetrics and Gynaecology, 2006, 113( 11): 1 128.
  • 5French! Australian Atosiban Investigators Group. Treatme?nt of preterm labor with the oxytocin antagonist atosiban. a double-blind, randomized, controlled comparison with salbutamol[J].European J of Obstetrics & Gynecology and Reproductive Biology, 2001 ,98 (2) : 177.
  • 6Moutiquin 1M, Sherman D, Cehen H, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effective?ness and safety study[J].Am J of Obstetrics and Gynecolo?gy,2000,182(5):1191.
  • 7The Worldwide Atosiban versus Beta-agonists Study Gro?up. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour[J]. British J of Obstetrics and Gynaecol?ogy,2001,108(2):133.
  • 8Herbst A, Wide-Swensson D, Ingemarsson I, et al. Sig?nificant delay of birth in advanced preterm labor at 23 ges?tational weeks with an oxytocin antagonist[J]. European J of Obstetrics & Gynecology and Reproductive Biology, 2003,108(1):109.
  • 9Pierzynski P , Reinheimer TM, Kuczynski W. Oxytocin an?tagonists may improve infertility treatment[J]. American Society for Reproductive Medicine, 2007, 88( 1): 213.
  • 10Moraloglu 0, Tongue E, Var T, et al. Treatment with oxy?tocin antagonists before embryo transfer may increase im?plantation rates after IVF[J]. Reproductive Bio Medicine Online, 2010, 21 (3): 338.

二级参考文献25

  • 1赵云红,甘泉.早产治疗新进展[J].大理学院学报(综合版),2004,31(5):95-97. 被引量:4
  • 2龚培玉,王保贞,王蕙兮.住院新生儿疾病构成及病死率分析[J].蚌埠医学院学报,1995,20(5):311-313. 被引量:16
  • 3Ingemarsson I, Lamont RF. An update on the controversies of tocolytic therapy for the prevention of pretenn birth. Acta Obstet Gynecol Seand, 2003, 82 : 1-9.
  • 4The Worldwide Atosiban versus Beta-agonists Study Group.Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenerglc agonists in the treatment of preterm labour. Br J Obstet Gynanecol, 2001, 108: 133-142.
  • 5Shim JY, Park YW, Yoon BH, et al. Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. Br J Obstet Gynanecol, 2006, 113 : 1228-1234.
  • 6Tsatsaris V, Carbonne B, Cabrol D. Atosiban for preterm labour. Drugs, 2004, 64: 375-382.
  • 7Di Renzo G, Al Saleh E, Mattei A, et al. Use of tocolytics : what is the benefit of gaining 48 hours for the fetus? Br J Obstet Gynanecol, 2006, 113: 72-77.
  • 8Romero R, Sibai BM, Sanchez-Ramos L, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double, blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol, 2000, 182: 1173-1183.
  • 9Kashanian M, Akbarian AR, Soltanzadeh M. Atosihan and nifedipin for the treatment of preterm labor. Int J Gynaecol Obstet, 2005, 91 : 10-14.
  • 10Husslein P, Roura L, Dudenhausen J, et al. Clinical practice evaluation of atosihan in pretenn labour management in six European countries. Br J Obstet Gynanecol, 2006, 113: 105-110.

共引文献115

同被引文献25

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部